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ABSTRACT In endothelial cells, neuropilin-1 (NRP1) binds vascular endothelial growth factor 
(VEGF)-A and is thought to act as a coreceptor for kinase insert domain-containing receptor 
(KDR) by associating with KDR and enhancing VEGF signaling. Here we report mutations in the 
NRP1 b1 domain (Y297A and D320A), which result in complete loss of VEGF binding. Overex-
pression of Y297A and D320A NRP1 in human umbilical vein endothelial cells reduced high-
affinity VEGF binding and migration toward a VEGF gradient, and markedly inhibited VEGF-
induced angiogenesis in a coculture cell model. The Y297A NRP1 mutant also disrupted 
complexation between NRP1 and KDR and decreased VEGF-dependent phosphorylation of 
focal adhesion kinase at Tyr407, but had little effect on other signaling pathways. Y297A 
NRP1, however, heterodimerized with wild-type NRP1 and NRP2 indicating that nonbinding 
NRP1 mutants can act in a dominant-negative manner through formation of NRP1 dimers with 
reduced binding affinity for VEGF. These findings indicate that VEGF binding to NRP1 has 
specific effects on endothelial cell signaling and is important for endothelial cell migration and 
angiogenesis mediated via complex formation between NRP1 and KDR and increased signal-
ing to focal adhesions. Identification of key residues essential for VEGF binding and biological 
functions provides the basis for a rational design of antagonists of VEGF binding to NRP1.
INTRODUCTION
Neuropilins-1 and -2 (NRP1 and NRP2) are transmembrane glyco-
proteins with large extracellular regions containing two CUB (homo-
logy with complement binding factors C1s/C1r, sea urchin epidermal 
growth factor [uEGF] and Bone Morphogenetic Protein 1 [BMP1]) 
homology domains (a1, a2), two coagulation factor V/VIII homology 
domains (b1, b2), and a MAM (homology with meprin, A5 antigen, 
and receptor tyrosine protein phosphatase m) domain (Pellet-Many 
et al., 2008). In addition, they have a transmembrane domain and a 
short intracellular domain with no clearly defined signaling function 
(Fujisawa and Kitsukawa, 1998; Rossignol et al., 2000). The impor-
tance of NRP1 for vascular and neuronal development has been es-
tablished by the generation of knockout mice, which are embryonic 
lethal with severe defects in the nervous system and vasculature 
(Kitsukawa et al., 1997; Kawasaki et al., 1999). Distinct sites in NRP1 
bind semaphorins and vascular endothelial growth factor (VEGF) 
family members to mediate the role of these ligands in neurons 
and endothelial cells, respectively (He and Tessier-Lavigne, 1997; 
Kolodkin et al., 1997; Soker et al., 1998; Gu et al., 2002). The major 
VEGF binding site is located in the b1 domain with some contribu-
tion of the b2 domain, whereas the a1/a2 together with the b1/b2 
domains are critical for recognition of Sema3A (Gu et al., 2002).
VEGF or VEGF-A is a specific mitogen for vascular endothelial 
cells which stimulates vasculogenesis and angiogenesis (Holmes 
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Figure 1B. Point mutations were introduced to evaluate the impor-
tance of these and other residues for VEGF-A165 binding. Full-length 
NRP1 expression plasmids were generated in which Tyr-297 or Asp-
320 had been replaced by alanine. Wild-type (WT) and mutant ver-
sions of NRP1 expression constructs were transfected into COS7 
cells, which express little endogenous NRP1. Both mutants and WT 
NRP1 were expressed to a similar level as judged by Western blot 
and flow cytometry, and immunofluorescence staining indicated a 
similar subcellular localization to the plasma membrane (Figure 1, 
C–E). Next we tested the ability of the NRP1 mutants to bind bioti-
nylated VEGF-A165 (bt-VEGF-A165) when expressed in COS7 cells. 
As shown in Figure 1F, cells expressing WT NRP1 showed increasing 
specific VEGF-A165 binding over a range of VEGF-A165 concentra-
tions. In contrast, the Y297A point mutation showed no specific 
VEGF-A165 binding at any bt-VEGF-A165 concentrations tested, con-
sistent with our previous results (Jarvis et al., 2010). Next we com-
pared the effect of the Y297A mutation with other mutations. Similar 
to Y297A, D320A also abrogated VEGF-A165 binding (Figure 1G). 
Effects of mutations of other residues comprising the VEGF-A165 
binding pocket on binding were also examined (Figures 1A 
and 2C).
Heparin increases VEGF-A165 binding to NRP1 and promotes re-
ceptor dimerization of isolated proteins (Vander Kooi et al., 2007). 
We therefore asked if heparin would rescue the loss of VEGF-A165 
binding to Y297A NRP1 and other NRP1 VEGF binding mutants. 
COS7 cells were transfected with WT and mutant forms of NRP1, 
and VEGF binding was measured in the presence and absence of 
heparin. Heparin increased the binding of VEGF-A165 to WT NRP1 
but had no effect on VEGF-A165 binding to the W301A, D320A, 
D320A, and Y353A mutants (Figure 2, A–C). Heparin, however, was 
able to enhance VEGF binding to T316A, T349A, K351A, and 
W411A mutants, all of which displayed markedly reduced binding in 
the absence of heparin (Figure 2C).
The NRP1 b1 domain is also essential for Sema3A binding (Gu 
et al., 2002). It was therefore important to examine the effect of the 
Y297A mutation on the binding of Sema3A. Measurement of Se-
ma3A binding to WT and Y297A NRP1 expressed in COS7 showed 
that Sema3A binding increased with increasing levels of NRP1 ex-
pression, but revealed no difference between these two forms of 
NRP1 in their relative ability to bind Sema3A (Figure 2D).
NRP1 mutants unable to bind VEGF-A165 inhibit binding 
to WT NRP1 and NRP2
Next we investigated the effect of the Y297A mutation on the ability 
of WT NRP1 to bind VEGF-A165. Cotransfection of WT and different 
amounts of mutant expression plasmid resulted in increasing inhibi-
tion of high-affinity bt-VEGF-A165 binding correlating with increas-
ing levels of Y297A NRP1 expression, indicating a dominant-nega-
tive effect of the VEGF-binding mutant on bt-VEGF-A165 binding in 
COS7 cells (unpublished results). We next examined whether Y297A 
NRP1 expression could similarly inhibit VEGF binding to endoge-
nous NRP1 in human umbilical vein endothelial cells (HUVECs). In 
addition, because many endothelial cells, including HUVECs, coex-
press NRP1 and NRP2, and both are known to bind VEGF-A165, we 
also examined whether non-VEGF-binding NRP1 mutants affected 
VEGF-A165 binding to NRP2. Due to the low sensitivity of bt-VEGF-
A165 binding, however, subsequent binding studies used 125I-VEGF-
A165 (Jia et al., 2006).
125I-VEGF-A165 binding was observed in COS7 cells expressing 
either NRP1 or NRP2 (Figure 3A), although determination of bind-
ing at different 125I-VEGF-A165 concentrations indicated that bind-
ing to NRP2 was significantly lower in affinity compared with NRP1, 
and Zachary, 2005). VEGF acts through the tyrosine kinase recep-
tors, VEGFR1 and VEGFR2 (kinase insert domain-containing recep-
tor; KDR). In particular, KDR is crucial in mediating VEGF signaling in 
endothelial cells by activating several different signaling cascades 
with different physiological functions including survival, prolifera-
tion, migration, vascular permeability, tubulogenesis, NO and pros-
tanoid biosynthesis, and gene expression (Gille et al., 2001). VEGF 
binding to KDR activates phosphatidylinositol 3-kinase and Akt/pro-
tein kinase B, a major pathway responsible for cell survival (Gerber 
et al., 1998; Thakker et al., 1999). In addition, VEGF is a strong acti-
vator of phospholipase Cγ, which in turn mediates activation of 
Extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2), 
protein kinase C, and protein kinase D pathways. This activation 
results in diverse biological responses including increased gene ex-
pression, mitogenesis, cell migration, and prostacyclin production 
(Gliki et al., 2001; Takahashi et al., 2001; Evans et al., 2008). Another 
important mediator of VEGF signaling in endothelial cells is the 
Src/focal adhesion kinase (FAK) pathway, which plays an important 
role in cell motility and actin cytoskeleton organization (Abedi and 
Zachary, 1997; Abu-Ghazaleh et al., 2001). Whereas KDR is crucial 
for all these VEGF effects in endothelial cells, NRP1 is particularly 
important for cell motility and chemotactic migration but has little 
effect on cell division (Pan et al., 2007).
NRP1 lacks any known enzymatic activity and is thought to func-
tion in endothelial cells by enhancing VEGF binding to KDR and 
downstream signaling events (Soker et al., 2002). VEGF-A165 pro-
motes the formation of a complex of NRP1 and KDR in endothelial 
cells, which is thought to be important for optimal VEGF signaling 
and function (Soker et al., 2002). In addition, the cytosolic domain of 
NRP1 is required for the interaction of NRP1 and KDR (Prahst et al., 
2008). This domain of NRP1 also interacts with GIPC/Synectin, which 
is implicated in endothelial cell migration and angiogenesis (Cai and 
Reed, 1999; Gao et al., 2000; Chittenden et al., 2006; Wang et al., 
2006).
While there is compelling evidence for an essential role of NRP1 
in angiogenesis, the precise contribution of VEGF binding to NRP1 
in angiogenic or endothelial functions of NRP1 remains unclear. Fur-
thermore, some evidence suggests that NRP1 may act indepen-
dently of VEGF and KDR in stimulating cell migration and adhesion 
(Wang et al., 2003; Murga et al., 2005). The objective of this study 
was to elucidate the role of VEGF binding to NRP1 in endothelial 
cell function by mutational analysis of residues in the putative VEGF 
binding pocket within the b1 domain essential for VEGF binding. In 
this report we describe a mutant form of NRP1 (Y297A NRP1), which 
cannot bind VEGF (Jarvis et al., 2010). Overexpression of this NRP1 
mutant in endothelial cells reduces complex formation between en-
dogenous NRP1 and KDR and impairs migration of these cells to-
ward a VEGF gradient and angiogenesis in a coculture model. 
Y297A NRP1 also selectively decreased phosphorylation of FAK at 
Y407 in endothelial cells. These results show the importance of 
VEGF binding to NRP1 in cell migration, and signaling linked to the 
regulation of actin cytoskeletal dynamics and formation of focal ad-
hesions.
RESULTS
Identification of NRP1 b1 domain residues essential 
for VEGF-A165 binding
Computational analysis of the b1 domain based on the crystal struc-
ture of NRP1 (Lee et al., 2003) revealed a putative ligand-binding 
pocket, which includes the amino acid residues Tyr-297 and Asp-320 
(Figure 1A). These residues are evolutionarily conserved between 
species and are also identical in NRP2, as shown for Tyr-297 in 
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FIGURE 1: NRP1 b1 domain residues required for VEGF-A165 binding. (A) A structural model of the VEGF binding 
pocket (yellow sphere) in the b1 domain of human NRP1 was generated computationally from the known b1 domain 
structure. Amino acids predicted to be critical for VEGF-A165 binding are labeled. (B) The NRP1 sequence of amino acids 
291–300 from different species and human NRP2 were aligned. The Tyr-297 residue is shown in bold. (C) COS7 cells 
were transfected with empty expression vector (control), WT NRP1 (WT), or mutant NRP1 (Y297A, D320A) expression 
plasmids. Western blots for NRP1 and GAPDH were performed using whole-cell extracts 48 h after transfection. 
(D) Immunofluorescence staining of COS7 cells expressing WT and mutant NRP1 constructs, as indicated, with antibody 
to NRP1 (green). (E) Flow cytometric analysis of NRP1-expressing cells was performed in COS7 cells transfected with 
WT, Y297A, or D320A NRP1 expression plasmids as indicated. (F) COS7 cells were infected with adenoviruses 
expressing WT or Y297A NRP1. Binding assays for bt-VEGF-A165 were performed with indicated amounts of VEGF as 
shown 48 h after infection. (G) COS7 cells were transfected with expression plasmids encoding WT, Y297A, or D320A 
NRP1 as indicated. Total specific binding of bt-VEGF-A165 was measured 48 h after transfection. Data represent means ± 
SD of values obtained from four to six independent experiments.
Volume 22 August 1, 2011 Role of VEGF binding to NRP1 | 2769 
cells, but increasing multiplicity of infection (MOI) using AdWT 
NRP1 produced no further augmentation of binding. In contrast, 
AdY297A NRP1 or AdD320A NRP1 decreased 125I-VEGF-A165 
binding, the degree of inhibition increasing with increasing MOI, 
reaching ∼45 and 27% inhibition at the highest MOI tested for 
AdY297A NRP1 and AdD320A NRP1, respectively (Figure 3D). 
Because HUVECs also express NRP2, KDR, and VEGFR1/Flt1, 
the 125I-VEGF-A165 binding to HUVECs uninhibited by even the 
highest mutant NRP1 MOI is likely to reflect 125I-VEGF-A165 bind-
ing to other VEGF-A receptors.
Our findings taken together indicate that the dominant-negative 
effects of non-VEGF-binding NRP1 b1 domain mutants on high-af-
finity binding of VEGF-A165 can be mediated via effects on both 
with Kd values of 8 and 0.3 nM for NRP2 and NRP1, respectively 
(unpublished data), consistent with previously reported Kd values 
of 5.2 and 0.5 nM for NRP2 and NRP1 (Geretti et al. 2007). Trans-
fection with increasing amounts of plasmid cDNA encoding Y297A 
NRP1 strongly inhibited 125I-VEGF-A165 binding in COS7 cells 
coexpressing WT NRP1 with >80% inhibition at the highest Y297A 
NRP1/WT NRP1 ratio, and similarly reduced 125I-VEGF-A165 bind-
ing in COS7 cells coexpressing WT NRP2 plasmid with a maximum 
90% inhibition (Figure 3A). To assess the contributions of different 
VEGF receptors to high-affinity 125I-VEGF-A165 binding to en-
dothelial cells, 125I-VEGF-A165 binding was determined in HUVECs 
after knockdown of NRP1, NRP2, and KDR using targeted siRNAs 
(Figure 3B). As shown in Figure 3C, knockdown of NRP1, NRP2, 
and KDR significantly reduced total specific 125I-VEGF-A165 bind-
ing by ∼30, 25, and 30%, respectively. We next addressed whether 
Y297A NRP1 could exert a dominant- negative effect on VEGF-
A165 binding to endogenously expressed NRPs in HUVECs. To 
achieve a high efficiency of transduction, HUVECs were infected 
with adenoviruses expressing control protein (AdGFP), WT NRP1 
(AdWT NRP1), Y297A NRP1 (AdY297A NRP1), or D320A NRP1 
(AdD320A NRP1). Expression of AdWT NRP1 enhanced 125I-VEGF-
A165 binding above the level in uninfected or in AdGFP-infected 
FIGURE 2: Effect of heparin on VEGF-A165 binding to WT NRP1 and 
b1 domain mutants. (A) VEGF-A165 binding assay to WT NRP1 
expressing COS7 cells in the presence of increasing amounts of 
heparin. Data are expressed as mean fold changes ± SD in binding 
from three independent experiments; *p < 0.05 and **p < 0.01 vs. 
no heparin. (B) VEGF-A165 binding in the absence or presence of 
1 μg/ml heparin to WT and Y297A NRP1; **p < 0.01 vs. no heparin. 
(C) VEGF-A165 binding in the absence or presence of 1 μg/ml heparin 
to WT NRP1 and NRP1 mutants, as indicated. Data are expressed as 
mean fold changes ± SD from three independent experiments; 
*p < 0.05 and ***p < 0.001 vs. WT + heparin. (D) Binding assay for 
Sema3A in COS7 infected with WT or Y297A NRP1 expressing 
adenoviruses at the indicated MOI. Data represent mean fold 
changes ± SD from three independent experiments.
FIGURE 3: Overexpression of Y297A NRP1 reduces VEGF-A165 
binding. (A) Binding assay of 125I-VEGF-A165 in COS7 cells transfected 
with fixed amounts of either WT NRP1 or WT NRP2, and increasing 
amounts of Y297A NRP1 expression plasmids. Numbers below the 
bars are ratios of Y297A to WT plasmids. Data represent mean 
specific binding ± SD from three independent experiments. 
(B) HUVECs were transfected with control siRNA (NC) and siRNAs 
targeted to NRP1, NRP2, or KDR. Cell lysates were immunoblotted 
48 h later with the antibodies indicated. (C) HUVECs were transfected 
with control siRNA (NC) and siRNAs targeted to NRP1, NRP2, or KDR, 
and, 48 h after transfection, 125I-VEGF-A165 binding was determined in 
the presence or absence of a 100-fold excess unlabeled VEGF-A165. 
The data shown are values for specific binding expressed as means ± 
SD from three independent experiments; *p < 0.05 and **p < 0.01 
vs. NC. (D) HUVECs were infected with adenoviruses expressing GFP, 
WT NRP1, Y297A, or D320A NRP1 at different MOIs as indicated. 
After 72 h, 125I-VEGF-A165 binding was determined in the presence or 
absence of a 100-fold excess unlabeled VEGF-A165. The data shown 
are values for specific binding expressed as means ± SD from three 
independent experiments; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. 
no virus.
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tin-coated plates consistent with previous findings (unpublished re-
sults; Murga et al., 2005). In contrast, adhesion assays performed in 
the presence or absence of VEGF-A165 in HUVECs infected with Ad-
LacZ, AdWT NRP1, or AdY297A NRP1 showed no significant differ-
ences in the attachment of HUVECs after 48 h (Figure 5C). VEGF-
A165 treatment also had no significant effect on adhesion.
VEGF-A165 binding to NRP1 is required for FAK signaling
An important pathway involved in VEGF-induced migration is phos-
phorylation of the nonreceptor tyrosine kinase FAK (Abedi and 
Zachary, 1997; Abu-Ghazaleh et al., 2001). Recent findings suggest 
that FAK phosphorylation at Y407 plays an important role in VEGF-
stimulated signaling leading to endothelial cell migration (Le Boeuf 
et al., 2006). To address the specific role of VEGF binding to NRP1 
NRP1 and NRP2, but also suggest that these mutants do not have a 
general inhibitory effect on 125I-VEGF-A165 binding to its other re-
ceptors when overexpressed in endothelial cells.
VEGF-A165 binding to NRP1 is required for complex 
formation between NRP1 and KDR
It was next examined whether the Y297A VEGF-binding mutant was 
able to perturb NRP1 complexation with KDR following treatment 
with VEGF-A165 (Soker et al., 2002). To address this question, 
HUVECs were infected with adenovirus expressing V5-tagged WT 
NRP1 or V5-Y297A NRP1, and coimmunoprecipitations were per-
formed using anti-V5 as the immunoprecipitating antibody followed 
by Western blots for KDR and for KDR phosphorylated at Y1175. 
VEGF-A165 promoted complex formation between KDR and NRP1 
in cells overexpressing V5-WT NRP1 as indicated by the detection 
of KDR and KDR phosphorylation at Y1175 in V5-WT NRP1 immu-
noprecipitates (Figure 4, A and B). In contrast, VEGF-induced NRP1/
KDR complex formation was strongly inhibited in cells expressing 
the binding- deficient V5-Y297A NRP1 mutant even though immu-
noprecipitation of V5-Y297A NRP1 was similar to that for V5-WT 
NRP1 (Figure 4, A and B).
A mechanism through which the Y297A NRP1 mutant could ex-
ert a dominant-negative effect on VEGF responses is the formation 
of heterodimers with WT NRP1 and NRP2. Such mutant/WT het-
erodimers would have a reduced capacity to bind VEGF-A165, and 
this in turn would be predicted to impair biological functions and 
signaling dependent on VEGF-A165 binding to NRP1 or on NRP2. To 
determine whether Y297A NRP1 could heterodimerize with WT 
NRP1, YFP-tagged Y297A NRP1 was coexpressed in COS7 cells 
with V5-tagged NRP1, and immunoprecipitates were prepared us-
ing anti-V5 antibody and then blotted with antibody to green fluo-
rescent protein (GFP)/yellow fluorescent protein (YFP). As shown in 
Figure 4C, YFP-Y297A NRP1 was specifically coimmunoprecipitated 
with V5-NRP1, whereas no coimmunoprecipitation was observed 
when untagged NRP1 was coexpressed with YFP-Y297A NRP1 or 
vice versa. Similarly, anti-YFP blots of V5 immunoprecipitates pre-
pared from COS7 cells coexpressing V5-Y297A NRP1 and YFP-
NRP2 demonstrated strong coimmunoprecipitation of mutant NRP1 
with NRP2 (Figure 4C). We also found that WT NRP1 and NRP2 were 
able to heterodimerize by coimmunoprecipitation of V5-NRP1 with 
YFP-NRP2 (unpublished results).
VEGF-A165 binding to NRP1 and NRP2 is important 
for migration of endothelial cells
We next investigated the role of VEGF-A165 binding to NRP1 in the 
migration of HUVECs. Knockdown of NRP1 or NRP2 expression us-
ing siRNAs markedly reduced VEGF-induced directed migration of 
HUVECs (Figure 5A), consistent with a role of both NRP1 and NRP2 
in endothelial migration. Infection with AdWT NRP1 had little effect 
on cell migration, whereas the Y297A mutant reduced the number 
of migrating cells compared with either control or WT adenovirus 
(Figure 5B). Expression of increasing levels of AdY297A NRP1 
caused a greater inhibition of VEGF-A165-induced migration, with 
90% inhibition at the highest titer selected and, similarly, AdD320A 
NRP1, which also prevented VEGF-A165 binding to NRP1, inhibited 
VEGF-A165–induced migration of HUVECs to a similar extent as 
Y297A (Figure 5B).
Because NRP1 has also been reported to be important for en-
dothelial cell adhesion, we examined whether non-VEGF-binding 
NRP1 mutants could affect adhesion of HUVECs to fibronectin. 
Knockdown of NRP1 using siRNA caused a modest, although statis-
tically significant, decrease in the adhesion of HUVECs to fibronec-
FIGURE 4: VEGF-A165 binding to NRP1 is essential for ligand-
dependent complex formation between NRP1 and KDR. (A) HUVECs 
infected with WT NRP1V5 or Y297A NRP1V5 adenoviruses were 
treated 72 h after infection with VEGF-A165 (+) or with vehicle (–) for 
10 min, and equal amounts of total cell lysates were used for 
immunoprecipitation with the indicated antibodies (IP) and detection 
by Western blotting as indicated (WB). (B) NRP1/KDR (left) and NRP1/
pKDR (right) association of five independent experiments was 
quantified. Data are expressed as means ± SD. (C) COS7 cells were 
transfected with the plasmid constructs indicated (+) and 48 h later 
were lysed. Then immunoprecipitations were performed with the 
antibodies indicated (IP), and immunoprecipitates were 
immunoblotted as indicated (WB) to determine associations between 
Y297A NRP1 and either WT NRP1 or WT NRP2.
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pressing cells (Figure 6A). ERK1/2 was activated to a similar extent 
by VEGF-A165 in GFP-, WT-, and Y297A-expressing cells. Our recent 
findings also indicate that NRP1 knockdown has no significant effect 
on VEGF-induced ERK1/2 activation (Evans et al., 2011). We also 
found that knockdown of NRP1 using targeted siRNA caused a 
marked and significant inhibition of VEGF-A165–stimulated KDR1175 
phosphorylation, compared with cells transfected with scrambled 
siRNA. In contrast, NRP2 siRNA caused no significant inhibition of 
VEGF-A165–stimulated KDR1175 phosphorylation (Figure 6B). The 
phosphorylation of FAK in response to VEGF-A165 treatment was 
also reduced by siRNA-mediated knockdown of NRP1 and NRP2 
(Figure 6B).
Effect of non-VEGF-binding NRP1 mutants on angiogenesis
An in vitro tubulogenesis assay was performed to test the effect of 
NRP1 VEGF-binding mutants on angiogenesis. HUVECs were cul-
tured on a layer of human dermal fibroblasts in the presence or ab-
sence of VEGF. Uninfected HUVECs or cells infected with GFP con-
trol virus showed an extended network of endothelial cell tubules 
after 7- to 10-d culture in the presence of VEGF, and cells cultured 
without VEGF showed little angiogenesis (Figure 7A). Whereas ex-
pression of WT NRP1 had no significant effect on the angiogenic 
response to VEGF, endothelial cells expressing the Y297A NRP1 
mutation exhibited a significantly decreased formation of this net-
work of tubules (Figure 7A) as judged by a decrease in both tubule 
length (Figure 7B) and a reduced number of branchpoints in the 
tubular network (Figure 7C). Furthermore, a similar inhibitory effect 
was produced by the nonbinding D320A NRP1 mutant (Figure 7).
DISCUSSION
The purpose of this study was to address the role of VEGF binding 
to NRP1 in endothelial cells through functional analysis of NRP1 mu-
tants defective in VEGF ligand binding. The b1 domain of NRP1 is 
essential for VEGF binding (Gu et al., 2002; Mamluk et al., 2002). 
We have identified Tyr-297 and Asp-320 as two of several residues 
within the b1 domain of NRP1 which are required for VEGF binding. 
These residues have recently been shown to be involved in binding 
of the NRP1 b1 domain in vitro to tuftsin, a natural tetrapeptide with 
some homology to the C terminus of VEGF-A165 (von Wronski et al., 
2006; Vander Kooi et al., 2007). Loss of binding in b1 domain mu-
tants is not likely due to major structural changes in the receptor 
because mutant protein expression and localization to the cell mem-
brane were not affected. We propose that the Y297A and D320A 
NRP1 mutants, when overexpressed in endothelial cells, act in a 
dominant-negative manner to inhibit VEGF binding to WT recep-
tors, by forming heterodimers with WT NRP1, which have reduced 
affinity for VEGF-A165. This hypothesis is supported by the finding 
that differentially tagged forms of Y297A and WT NRPs can be 
coimmunoprecipitated, indicating that these forms associate spon-
taneously in dimers or higher-order complexes. This finding sug-
gests that NRP1 homodimerization and NRP1/NRP2 heterodimeriza-
tion, and/or possibly oligomerization, may play an important role in 
the formation of high-affinity binding sites for VEGF-A165. Several 
domains in NRP1 may be important for dimerization, including the 
MAM, transmembrane, and C-terminal domains of NRP1 (Naka-
mura et al., 1998; Renzi et al., 1999; Roth et al., 2008). Heparin also 
promotes receptor dimerization and enhanced VEGF-A165 binding 
to NRP1, but failed to rescue VEGF-A165 binding to the Y297A mu-
tant NRP1, demonstrating the importance of interaction of the C 
terminus of VEGF-A165 with this residue in the b1 domain (Vander 
Kooi et al., 2007). The finding that heparin was able to partially re-
store VEGF-A165 binding to other NRP1 b1 domain mutants, which 
in this signaling pathway, HUVECs were infected with control GFP, 
WT NRP1, or Y297A NRP1 adenoviruses, and 72 h after infection 
quiescent cells were treated with VEGF-A165. VEGF-A165 stimulation 
of KDR phosphorylation at Y1175 was similar and not significantly 
different in HUVECs expressing WT and Y297A NRP1 (Figure 6A). 
Immunoblotting of lysates from VEGF-treated, infected cells showed 
that the phosphorylation of Y407 FAK was markedly reduced in cells 
expressing Y297A NRP1, whereas WT NRP1 had little effect 
(Figure 6A). Quantification of data from four independent experi-
ments showed that VEGF-A165 caused no significant increase in 
Y407 FAK phosphorylation after a 30-min treatment in Y297A NRP1–
expressing cells, whereas VEGF-A165 induced Y407 phosphorylation 
to a similar extent after 10 and 30 min in GFP- and WT NRP1–ex-
FIGURE 5: VEGF-A165 binding to NRP1 is required for migration but 
not for adhesion. (A) HUVECs were transfected with control siRNA 
(NC) or siRNA directed against NRP1 or NRP2 as indicated. Cell 
migration was measured in a transwell assay. Data represent the 
average number of migrated cells of three independent experiments 
± SD; *p < 0.05 vs. NC + VEGF. (B) Migration assay of HUVECs 
infected with adenoviruses expressing GFP, WT NRP1, Y297A, or 
D320A NRP1 in transwells at the MOIs indicated. Migrated cells 
were counted 72 h after infection. Data represent mean numbers of 
migrated cells ± SD from three independent experiments; *p < 0.05 
vs. GFP MOI 30, and **p < 0.01 vs. GFP MOI 90. (C) HUVECs 
were infected with adenoviruses expressing LacZ, WT NRP1 (WT), 
Y297A NRP1, or D320A NRP1 as indicated. After 72 h, the 
attachment of infected cells to fibronectin-covered wells was 
measured in the presence or absence of 25 ng/ml VEGF-A165. Data 
represent mean fold changes ± SD from three independent 
experiments.
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caused substantial loss of binding in the absence of heparin sug-
gests, however, that heparin is able to mediate binding interactions 
between the VEGF-A165 C terminus and the b1 domain. Although 
Sema3A binding to NRP1 also requires the b1 domain, the Y297A 
mutation does not affect the binding of Sema3A, and this allowed 
us to address the specific role of VEGF-A165 binding to NRP1.
The finding that expression of the Y297A and D320A NRP1 mu-
tants reduced high-affinity VEGF-A165 binding to endothelial cells 
and VEGF-A165 stimulation of endothelial cell migration and tubulo-
genesis in a coculture model provides strong 
evidence that VEGF-A165 binding to NRP1 
plays an important role in migratory re-
sponses important for angiogenesis. Previ-
ous work showed that a peptide antagonist 
that selectively and effectively blocks VEGF 
binding to NRP1 had no significant effects 
on VEGF stimulation of proliferation or cell 
survival (Jia et al., 2006) and that an NRP1 
antibody that inhibits VEGF binding to NRP1 
only slightly reduced VEGF stimulation of 
HUVEC proliferation, but caused much 
greater inhibition of cell migration (Pan et 
al., 2007). Therefore, previous data do not 
indicate a major role for VEGF binding to 
NRP1 in the mitogenic response to VEGF. 
Although nonbinding NRP1 mutants re-
duced VEGF-A165 binding to HUVECs by up 
to 45%, the substantial residual binding un-
affected by these mutants even at the high-
est levels of adenovirus used argue strongly 
that functional dominant-negative effects of 
Y297A and D320A NRP1 on migration and 
branching tubulogenesis are not due to a 
nonspecific effect on binding to other re-
ceptors, such as KDR. Interestingly, neither 
Y297A NRP1 nor VEGF-A165 treatment sig-
nificantly affected endothelial cell adhesion 
to fibronectin or poly-l-lysine, although 
NRP1 knockdown did inhibit adhesion. Con-
sistent with this observation, Tyr-297 is not 
part of an 18-amino-acid stretch in the b1 
and b2 domains of NRP1 reported to be suf-
ficient for NRP1-mediated cell adhesion 
(Shimizu et al., 2000). Previous studies sug-
gest that NRP1-mediated endothelial cell 
adhesion is independent of VEGF and Se-
ma3A ligands (Murga et al., 2005), and our 
data now provide direct support for this 
conclusion.
Inhibition of the VEGF migratory re-
sponse by Y297A NRP1 may be due, as dis-
cussed earlier, to formation of dimers with 
endogenous WT NRP1, which have reduced 
affinity for VEGF-A165, and as a result either 
do not participate in complexation with 
KDR, or form NRP1/KDR complexes with re-
duced functionality. Previous studies ob-
tained different results for NRP1/KDR com-
plex formation, some demonstrating a 
strong dependence of NRP1 and KDR as-
sociation on VEGF-A treatment (Soker et al., 
2002; Pan et al., 2007), whereas others 
found that complex formation was a largely constitutive process, 
occurring in the absence of VEGF-A (Whittaker et al., 2001; Shraga-
Heled et al., 2007). The differences between these studies may re-
flect technical factors relating to the conditions and reagents used 
for immunoprecipitation, as well as choice of endothelial cell type, 
and heterogeneities among different cell preparations. We found 
that NRP1 complex formation with KDR was strongly induced by 
treatment with VEGF-A165. We do not preclude, however, that con-
stitutive formation of NRP1/KDR complexes may be biologically 
FIGURE 6: VEGF binding to NRP1 is important for FAK Tyr-407 phosphorylation in endothelial 
cells. (A) HUVECs were infected with GFP, WT NRP1, or Y297A NRP1. Growth medium was 
replaced by serum-free medium 72 h after infection, and the following day quiescent infected 
cells were treated with VEGF-A165 for the times indicated. Whole-cell extracts were then 
analyzed by using Western blotting with the indicated antibodies. Blots from panel A (n = 4) 
were quantified by scanning densitometry to determine the extent of phosphorylation KDR 
Y1175 and FAK Y407 (right). The bar graph shows the mean ratio of phosphorylated to total 
protein from four independent experiments ± SD; *p < 0.05 vs. WT 30 min VEGF treatment. 
(B) HUVECs were transfected with negative control siRNA (NC) or siRNAs targeted to NRP1 or 
NRP2, and 48 h later were treated with 25 ng/ml VEGF-A165 for 10 or 30 min. Cells were then 
lysed and immunoblotted as indicated. Blots were quantified as described earlier; *p < 0.05 vs. 
control siRNA.
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in response to these cytokines (Sulpice et al., 2009). Because HGF 
can also bind to NRP1 (Sulpice et al., 2008) it will be interesting to 
investigate in future work the effect of the Y297A NRP1 mutant on 
HGF signaling. Our finding that Y297A NRP1 reduces FAK phos-
phorylation at Tyr-407 suggests that VEGF-A165 binding to NRP1 
plays a key role in focal adhesion signaling important for cell migra-
tion. It is noteworthy that Y297A NRP1 expression had no significant 
effect on VEGF-A165–induced activation of KDR or ERK1/2 com-
pared with WT NRP1. The lack of effect of Y297A NRP1 on KDR 
phosphorylation probably reflects the fact that KDR activation by 
VEGF-A165 is mainly independent of NRP1. This conclusion is con-
sistent with the finding that NRP1-directed antibody, which selec-
tively blocks VEGF-A165 binding to NRP1 and inhibits VEGF-A165–
induced endothelial cell migration, had little effect on KDR or ERK 
activation in HUVECs (Pan et al., 2007). Taken together, these find-
ings indicate that NRP1 plays a role in specific KDR signaling path-
ways such as FAK Y407, but is dispensable for KDR activation and 
signaling pathways mediated via KDR phosphorylation at Y1175 
such as ERK activation.
We also identified an important role for NRP2 in mediating VEGF-
induced migration in HUVECs, based on the inhibitory effects of 
NRP2 knockdown. 125I-VEGF-A165 exhibited specific binding to cells 
expressing NRP2, but bound to NRP2 with significantly lower affinity 
than to NRP1. These data are consistent with a recent study report-
ing a dissociation constant (Kd) of 5.2 nM for NRP2, compared with 
the Kd for VEGF-A165 binding to NRP1 of 0.2–0.3 nM (Soker et al., 
1998; Geretti et al., 2007). The finding that overexpression of Y297A 
NRP1 was able to reduce 125I-VEGF-A165 binding to NRP2 and 
strongly inhibit VEGF-induced cell migration indicates that this mu-
tant also exerts a dominant-negative effect on the NRP2-dependent 
migratory response of endothelial cells. Because Y297A NRP1 was 
able to associate with NRP2, this effect is likely to be due to the for-
mation of Y297A NRP1/NRP2 heterodimers with a reduced capacity 
to bind VEGF and to participate in functional complexes of NRP2 
with other receptors. Given that weak binding of VEGF-A165 appears 
to occur at concentrations of VEGF-A165 required for biological ef-
fects in endothelial cells such as migration or angiogenesis, such as 
were used in this study, the biological relevance of VEGF-A165 bind-
ing to NRP2 in cells is unclear. Thus it is plausible that the major 
mechanism through which NRP2 contributes to VEGF-A165–depen-
dent migration in human endothelial cells is through heterodimeriza-
tion with NRP1 rather than direct binding of VEGF-A165 to NRP2.
In this article, we have identified residues essential for VEGF-
A165 binding to NRP1, which constitute part of the putative binding 
pocket for VEGF-A165 in the NRP1 b1 domain, defined by computa-
tional analysis of the b1 domain structure, and inferred from the 
crystal structure of the b1 domain. Functional analysis of two bind-
ing deficient NRP1 mutants revealed an unexpected dominant neg-
ative effect of these mutants on VEGF-A165 binding to WT NRP1 
and on VEGF-A165 stimulation of migration and signaling mediating 
cell migration. These findings provide strong evidence for the im-
portance of VEGF-A165 binding to NRP1 in endothelial cell migra-
tion, and also highlight the role of NRP1 in linking the VEGF-A165/
KDR axis to specific chemotactic signaling pathways. Identification 
of key residues in the VEGF-A165 binding pocket of NRP1 will also 
be helpful in the future rational design of small molecule inhibitors 
of ligand binding to NRP1.
MATERIALS AND METHODS
Molecular modeling
Possible binding sites in the NRP1 b1 domain were searched using 
the SYBYL SITEID module (SYBYL 7.0; Tripos, St. Louis, MO).
important, and although the mechanisms underlying this phenom-
enon are currently unclear, one possibility is that endogenous VEGF-
A165 production may mediate basal association between NRP1 and 
KDR acting in either an autocrine or intracrine manner. Our data 
further showed that expression of the Y297A NRP1 mutant pre-
vented VEGF-A165–induced complex formation between NRP1 and 
KDR, indicating that VEGF-A165 binding to NRP1 is essential for for-
mation of NRP1/KDR heterodimers either alone or as homodimers 
or oligomers with WT NRP1, and that these heterocomplexes may 
be rapidly destabilized by subsequent VEGF-A165 binding to KDR. 
We previously reported that siRNA-mediated knockdown of NRP1 
in HUVECs reduced KDR expression both under basal unstimulated 
conditions or after VEGF-A165 stimulation (Holmes and Zachary, 
2008). Thus it is plausible that, in the presence of an NRP1 mutant 
unable to bind VEGF-A, NRP1/KDR heterocomplexes may be rap-
idly destabilized by subsequent VEGF-A165 binding to KDR in part 
because of increased KDR lability. This possibility warrants further 
investigation.
Generation of the Y297A NRP1 VEGF-A165 binding mutant also 
provided a tool with which we were able to dissect the contribution 
of NRP1 to VEGF-A165 endothelial cell signaling. The KDR-HSP90-
FAKpTyr407 pathway is critical for the assembly of focal adhesions 
and endothelial cell migration (Rousseau et al., 2000; Le Boeuf et al., 
2004). VEGF stimulates the tyrosine phosphorylation of FAK and its 
major substrate, paxillin (Abedi and Zachary, 1997). Several phos-
phorylation sites in FAK mediate signaling from receptor tyrosine 
kinases and integrins to promote cell migration and blood vessel 
morphogenesis in vivo (Sieg et al., 2000; Ilic et al., 2003), and Tyr-
407 phosphorylation plays a critical role in mediating the response 
to VEGF (Le Boeuf et al., 2006). Both VEGF and hepatocyte growth 
factor (HGF) activate FAK in endothelial cells with different kinetics, 
however, and FAK is recruited to different subsets of focal adhesions 
FIGURE 7: VEGF binding to NRP1 is important for angiogenesis in a 
coculture assay. (A) Human dermal fibroblasts were grown in a 24-well 
format to confluence. HUVECs were infected with adenoviruses 
encoding GFP, WT NRP1, Y297A NRP1, or D320A NRP1, and 72 h 
after infection were seeded (10,000 cells per well) on top of the 
fibroblast cell layer. Cell cocultures were then maintained for 7 d in 
the presence of 0.5% serum alone (-VEGF) or 0.5% serum plus 25 ng/
ml VEGF-A165 (+VEGF). Endothelial cells were then visualized by 
immunostaining for vWF. (B and C) Quantitation of coculture assays in 
(A). The bar graph shows the mean ± SD total tubule length (B) or 
number of branchpoints (C) counted in three independent 
experiments; ***p < 0.001 vs. GFP + VEGF.
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Biotec, Bisley, UK) for 20 min at 4°C. Cells were washed in PBS/1% 
BSA/20 mM HEPES. Data were analyzed with the FACSCalibur sys-
tem (BD Biosciences, Franklin Lakes, NJ).
Immunoprecipitations
Coimmunoprecipitations involving NRP1, KDR, and V5-tagged and 
YFP-tagged NRP1 and NRP2 constructs were performed essentially 
as described (Prahst et al., 2008). Briefly, whole-cell extracts from 
HUVECs were prepared in lysis buffer and incubated with 1 μg of 
antibody and 30 μl of Sepharose G beads overnight at 4°C with ro-
tation. Precipitated protein complexes were washed three times in 
ice-cold PBS containing protease and phosphatase inhibitors and 
eluted in 2× LDS buffer (Invitrogen) at 70°C for 10 min.
Tubulogenesis assay
In vitro angiogenesis was determined by using a coculture tubulo-
genesis assay (Friis et al., 2003). Briefly, human dermal fibroblasts 
were grown to confluence in 24-well plates in M106 medium sup-
plemented with low serum growth supplement (Invitrogen). 
Medium was replaced, and 10,000 HUVECs were plated on top of 
the fibroblast layer cultured in complete endothelial growth me-
dium supplemented with 1% FBS. HUVECs and fibroblasts were 
propagated in coculture for 7 d at 37°C and 5% CO2. Cells in 
coculture were fixed in absolute ethanol for 2 h at room tempera-
ture, and HUVECs were identified by incubating with anti–von 
Willebrand factor antibody in PBS-Tween 20 with 5% BSA over-
night at 4°C. Bound antibody was detected with biotinylated 
secondary antibody (Chemicon, Temecula, CA) and ABC (Vector 
Laboratories, Burlingame, CA) with diaminobenzidine staining 
(Sigma). Photomicrographs of von Willebrand factor–stained 
cocultures were analyzed using ImageJ software. The length of all 
tubular structures (stained endothelial cells) and the number of 
branching points were measured in four representative micro-
scopic fields per well.
Cell migration assay
Migration of HUVECs was measured as described previously using 
Transwell membranes (BD Biosciences; Evans et al., 2008).
Cell adhesion assay
Cell adhesion was measured using the InnoCyte ECM Cell Adhesion 
Assay with fibronectin-covered plates (Calbiochem, San Diego, 
CA).
VEGF-A165 and Sema3A binding assay
After transfection with NRP1 constructs, COS7 cells were washed in 
ice-cold PBS and incubated with 2 nM bt-rhVEGF-A165 (R&D Sys-
tems, Minneapolis, MN) in DMEM with 0.1% BSA for 2 h at 4°C with 
agitation. After incubation, cells were washed three times in ice-cold 
PBS and incubated with streptavidin-HRP (R&D Systems) in PBS with 
1% BSA for 30 min at room temperature with agitation. Cells were 
then washed three times in PBS before detection with substrate re-
agent (R&D Systems) for 15 min. The reaction was stopped with 
stopping solutions, and signal intensity was quantified using a Tecan 
Genios plate reader at A450 nm with a reference wavelength of 
595 nm. A Sema3A binding assay was performed as described 
(Narazaki and Tosato, 2006). Briefly, cells were blocked with PBS-
Tween 20 with 5% dry milk and then incubated with 1 μg/ml Se-
ma3A/Fc (R&D Systems) for 2 h at 4°C with agitation. The antibody 
solution was removed, and cells were washed three times with PBS-
Tween 20. Bound Sema3A was detected with anti- IgG/Fc-HRP an-
tibody (Autogen Bioclear, Calne, Wiltshire, UK).
Materials
Recombinant VEGF-A165 was obtained from Invitrogen (Carlsbad, 
CA). Heparin was purchased from Sigma (St. Louis, MO). Antibodies 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA) were 
NRP1 (sc-7239), NRP2 (sc-13117), KDR (sc-504), GAPDH (sc-20357), 
and α-tubulin (sc-8035). Phospho-FAK407 (44650G) and GFP 
(A6455) were obtained from Invitrogen; phospho-KDR (#2478), FAK 
(#3285), phospho-ERK (#9101) were obtained from Cell Signaling 
Technology (Danvers, MA); KDR (#101-M32) from ReliaTech (Wolfen-
büttel, Germany); vWF (ab6994) from Abcam (Cambridge, UK); and 
anti-V5 agarose (A7345) from Sigma.
Plasmids and adenoviral constructs
The open reading frames of human NRP1 and NRP2 were cloned 
into pENTR/D-TOPO by directional TOPO-cloning (Invitrogen, 
Paisley, UK). Subsequently, plasmid expression constructs 
(pcDNA3.2/V5-DEST) and adenoviral vectors encoding NRP1 con-
structs (pAd/CMV/V5-DEST) were generated by recombination us-
ing the gateway system (Invitrogen). Mutagenesis of human NRP1 in 
pENTR was performed using the QuickChange kit (Stratagene, La 
Jolla, CA). All constructs were confirmed by DNA sequencing. YFP-
tagged NRP1 WT, Y297A NRP1, and NRP2 were generated using 
the pcDNA6.2/YFP-GW/TOPO vector (Invitrogen).
Cell culture and transfection
HUVECs were purchased from Lonza (Basel, Switzerland) and cul-
tured in complete endothelial cell basal medium (Lonza) supple-
mented with 10% fetal bovine serum (FBS). The day before treat-
ment of HUVECs the culture medium was replaced by serum-free 
medium. COS7 cells were obtained from the ECACC (European 
Collection of Cell Cultures) and maintained in DMEM supple-
mented with 10% FBS (Invitrogen). Cells were transfected with Li-
pofectamine 2000 (Invitrogen), according to the manufacturer’s in-
structions.
Western blotting
After treatment, cells were washed in ice-cold phosphate-buffered 
saline (PBS) and lysed in radio-immunoprecipitation assay (RIPA) 
buffer (NEB, Hitchin, UK) with 0.5 μl/ml Protease Inhibitor Cocktail 
(Sigma, Poole, UK) and 1 mM phenylmethylsulfonyl fluoride. Pro-
teins were separated on NuPage 4–12% Bis-Tris gels using 3-(N-
morpholino)-propanesulfonic acid running buffer systems and trans-
ferred to Invitrolon polyvinylidene fluoride membranes (Invitrogen). 
Membranes were blocked in 5% nonfat dried milk in PBS and 0.1% 
Tween 20 and incubated with primary antibodies overnight at 4°C. 
Immunoreactive bands were detected by horseradish peroxidase 
(HRP)-conjugated secondary antibodies and chemiluminescent de-
tection (ECL Plus; GE Healthcare, Little Chalfont, UK).
Immunofluorescence staining
Cells were fixed in 4% formaldehyde in PBS followed by permeabi-
lization in 0.02% Triton X-100 in PBS. Fixed cells were incubated 
with anti-NRP1 (Santa Cruz) or Alexa Fluor phalloidin (Invitrogen) 
overnight at 4°C in 1% bovine serum albumin (BSA), 0.1% Tween 20 
in PBS. Confocal imaging was performed using a Bio-Rad (Hercules, 
CA) Radiance 2100 laser and upright Nikon Eclipse E1000 micro-
scope.
Flow cytometry
Confluent COS7 cells were harvested with dissociation buffer 
(C1914; Sigma) and washed with PBS/1% BSA/20 mM HEPES. Cells 
were incubated with anti-NRP1 antibody (CD304-PE; Miltenyi 
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